Pmv Pharmaceuticals, INC 10-Q quarterly reports

PMV Pharmaceuticals reports significant net losses and substantial doubt regarding its ability to continue as a going concern, despite progress in its lead drug candidate, rezatapopt.

PMV Pharmaceuticals reports a net loss of $18.0 million for Q1 2026, with operating expenses decreasing but interest income also declining, while maintaining sufficient cash for the next 12 months.

PMV Pharmaceuticals, Inc. reported increased net losses for the nine months ended September 30, 2025, while advancing its lead oncology candidate, rezatapopt, towards a pivotal Phase 2 study completion and future NDA submission.

PMV Pharmaceuticals reported a significant increase in net loss for Q2 2025, driven by higher research and development expenses for its lead oncology candidate, rezatapopt, while projecting liquidity until late 2026.

PMV Pharmaceuticals reports a net loss of $17.4 million for Q1 2025 while progressing its lead drug candidate, rezatapopt, through clinical trials.

PMV Pharmaceuticals reported a net loss of $19.2 million for the third quarter of 2024, while continuing to advance its lead product candidate, PC14586, through clinical trials.

PMV Pharmaceuticals reported a net loss of $1.2 million for the second quarter of 2024, while continuing to advance its lead product candidate, PC14586.

PMV Pharmaceuticals reported a net loss of $15.3 million for the first quarter of 2024, alongside a restructuring plan and advancements in their clinical trials.